Insight in the prediction of chemotherapy-induced nausea.
OBJECTIVE
To identify risk factors for chemotherapy-related nausea.


METHODS
We examined risk factors for nausea in 1,696 patients from three multicenter studies conducted from 1998 to 2004. All patients were beginning a chemotherapy regimen containing cisplatin, carboplatin, or doxorubicin. Nausea was assessed on a 1-7 scale four times a day for 4 days by diary.


RESULTS
First, average nausea for breast cancer patients receiving doxorubicin (mean = 2.31) was significantly greater than for other patients receiving doxorubicin (mean = 1.82), patients receiving cisplatin (mean = 1.88), and patients receiving carboplatin (mean = 1.45), Ps < 0.01. Second, mean nausea decreased steadily with age, P < 0.0001. Third, patients rating themselves more susceptible to nausea had significantly more nausea (adjusted mean = 2.51) than patients rating themselves less susceptible (adjusted mean = 1.92) and were 2.8 times more likely to experience severe nausea, Ps < 0.0001. Fourth, expected nausea was a significant predictor of average nausea, P = 0.034, but not severe nausea, P = 0.31. Last, no evidence that gender is a significant predictor of nausea in 299 patients with gender neutral cancers, P = 0.35.


CONCLUSIONS
Specific patient characteristics, especially younger age and perceived susceptibility to nausea, can help clinicians in the early identification of patients who are more susceptible to treatment-related nausea.
Roscoe
Joseph A
JA
James P. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. Joseph_Roscoe@urmc.rochester.edu
Morrow
Gary R
GR
Colagiuri
Ben
B
Heckler
Charles E
CE
Pudlo
Bryan D
BD
Colman
Lauren
L
Hoelzer
Karen
K
Jacobs
Andrew
A
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced* / Q000188:drug therapy / Q000453:epidemiology; D011346:Prochlorperazine / Q000627:therapeutic use; D012307:Risk Factors; D012702:Serotonin Antagonists / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology
D012702:Serotonin Antagonists; D004317:Doxorubicin; D016190:Carboplatin; D002945:Cisplatin; D011346:Prochlorperazine
Am J Health Syst Pharm. 1999 Apr 15;56(8):729-64
10326616
N Engl J Med. 1981 Oct 15;305(16):905-9
7024807
Curr Probl Cancer. 2006 Mar-Apr;30(2):40-98
16516693
ONS News. 2004;19(9 Suppl):61-2
15478591
J Support Oncol. 2004 Jan-Feb;2(1 Suppl 1):1-10, inside back cover; quiz 11
16117016
J Clin Oncol. 1997 Jan;15(1):116-23
8996132
J Pain Symptom Manage. 2003 Aug;26(2):731-42
12906958
Cancer. 2004 Dec 1;101(11):2701-8
15517574
J Clin Oncol. 1999 Sep;17(9):2971-94
10561376
Oncologist. 2007 Sep;12(9):1143-50
17914084
J Support Oncol. 2007 Feb;5(2 Suppl 1):5-12
17366928
Cancer Pract. 1995 Jul-Aug;3(4):247-53
7620490
Cancer. 2003 Jun 1;97(11):2880-6
12767103
Psychol Bull. 1988 Nov;104(3):307-25
3062654
Ann Behav Med. 2000 Spring;22(2):121-6
10962704
J Consult Clin Psychol. 1987 Feb;55(1):42-8
3553262
Support Care Cancer. 1997 Jul;5(4):307-13
9257427
J Pain Symptom Manage. 2008 Apr;35(4):381-7
18243641
Support Care Cancer. 2006 Apr;14(4):354-60
16450086
Cancer. 2008 Aug 1;113(3):654-61
18521919
Psychooncology. 2005 Jan;14(1):25-33
15386792
Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):143-50
17697032
Lancet Oncol. 2005 Oct;6(10):765-72
16198982
JAMA. 2002 Feb 6;287(5):622-7
11829702